EGFR and non-small cell lung carcinoma: The more focused strategy applied in the first-line setting to evaluate of the first and second-generation EGFR-TKIs, and more recently to ALK inhibitors, which limited enrollment to EGFR mutation-positive and ALK mutation-positive NSCLC, respectively, have been far more successful.